BackKailera Therapeutics Overview

Kailera Therapeutics Receivables

Kailera Therapeutics's receivables is $3.2M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$3.21M

Peer average / median

Loading

Kailera Therapeutics Receivables History

Loading

Kailera Therapeutics vs. peers: Receivables Comparison

Loading

Kailera Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Kailera Therapeutics (KLRA) FAQ

As of the most recent data (March 2026), KLRA shows a receivables of $3.2M. Scroll down for historical charts and peer comparison views.

Tracking KLRA's receivables over time shows whether Kailera Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $3.2M Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Kailera Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $3.2M) with ownership activity and broader fundamentals.

Kailera Therapeutics's receivables is $3.2M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.